



Pion Inc.  
10 Cook Street  
Billerica, MA 01821  
978-528-2020  
www.pion-inc.com

---

FOR IMMEDIATE RELEASE

**Konstantin Tsinman promoted to Chief Scientific Officer**

*Pion Inc. continues to strengthen position in pharmaceutical R&D with the on-going professional advancement of this leader in the global drug-development industry*

Billerica, MA, USA – March 1, 2016 – Pion announced the promotion of Dr. Konstantin Tsinman to Chief Scientific Officer. He will be responsible for all aspects of Pion’s research and development ventures as well as continuing to be Pion’s expert as he presents to the global drug-development industry.

*“I am privileged to be growing professionally along with a company as unique as Pion and I am honored to be promoted to a new role within the organization. This new title brings more responsibilities in elevating Pion’s research and applying it to existing as well as new products. I will continue striving to engage our team as well as our customers, collaborators, and peers in support of the goal to highlight the science that is behind all of our instrumentation and services.”—Dr. Konstantin Tsinman, CSO, Pion, Inc.*

Prior to his promotion, Dr. Tsinman was the Science & Research Director with Pion Inc. for 3 years. In his varying roles with Pion since 1998, he has driven many exciting developments and scientific breakthroughs. He was the principal developer of the first commercial Parallel Artificial Membrane Permeability Assay (PAMPA) instrument and, subsequently, the high-throughput method for measuring solubility—pH profiles.

He participates in numerous studies investigating physicochemical factors influencing the absorption potential of pharmaceutical compounds. Current activities include expanding the scope of applications for in situ UV fiber-optics, further implementation of derivative spectroscopy for real-time concentration monitoring of multi-component systems, and investigating the applicability of drug-selective potentiometric sensors.

Konstantin Tsinman received his PhD in Physics in 1994 from the Institute for Metal Physics in Kiev, Ukraine. He has been involved in multiple collaborative research projects with scientists from industry and academic institutions. In addition to co-authoring more than 25 articles published in primary scientific journals, Dr. Tsinman holds several patents.

*“During his more than 18 years at Pion, Dr. Tsinman has been a committed contributor to the scientific knowledgebase for UV detection systems, permeability science, solubility study techniques, and physico-chemical analysis—with results that are unprecedented in their scope and impact. We look forward to his future work as he leads both Pion and the scientific community into new areas of interest with his promotion to Chief Scientific Officer of Pion Inc.” —Mike Kelly, President, Pion, Inc.*



#### About Pion Inc.

Pion Inc. develops and manufactures instrumentation for compound testing in pharmaceutical R&D. These include high-precision fiber optic-based analytical instruments for solubility and dissolution measurements, as well as complete systems for permeability (PAMPA), solubility, and ionization. Additionally, Pion provides CRO services for solubility, permeability, dissolution,  $pK_a$ , and lipophilicity testing. More information is available at [www.pion-inc.com](http://www.pion-inc.com).

For more information, please contact:

Barb Schwartz / Content and Marketing Manager

[bschwartz@pion-inc.com](mailto:bschwartz@pion-inc.com)

919-264-3099

###